-
1
-
-
33750121597
-
Optimization of allogeneic transplant conditioning: Not the time for dogma
-
Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 2006;20:1701-5.
-
(2006)
Leukemia
, vol.20
, pp. 1701-1705
-
-
Deeg, H.J.1
Maris, M.B.2
Scott, B.L.3
Warren, E.H.4
-
2
-
-
33646119401
-
Hematopoietic stem-cell transplantation
-
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.
-
(2006)
N Engl J Med
, vol.354
, pp. 1813-1826
-
-
Copelan, E.A.1
-
3
-
-
33644909940
-
Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation
-
Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:472-9.
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 472-479
-
-
Kletzel, M.1
Jacobsohn, D.2
Duerst, R.3
-
4
-
-
33645734405
-
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
-
Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
-
(2006)
Nat Med
, vol.12
, pp. 401-409
-
-
Ott, M.G.1
Schmidt, M.2
Schwarzwaelder, K.3
-
5
-
-
0037189401
-
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
-
Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-13.
-
(2002)
Science
, vol.296
, pp. 2410-2413
-
-
Aiuti, A.1
Slavin, S.2
Aker, M.3
-
6
-
-
85036868041
-
Busulfan, fludarabine, and total body irradiation followed by allogeneic peripheral blood stem cell transplantation is an effective treatment for hematologic malignancies with acceptable toxicities in a high risk population [abstract 318]
-
Meyers G, Dunn A, Kovascovics TJ, et al. Busulfan, fludarabine, and total body irradiation followed by allogeneic peripheral blood stem cell transplantation is an effective treatment for hematologic malignancies with acceptable toxicities in a high risk population [abstract 318]. Biol Blood Marrow Transplant 2008;14(2 suppl 2):I17.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, Issue.2 SUPPL. 2
-
-
Meyers, G.1
Dunn, A.2
Kovascovics, T.J.3
-
7
-
-
0021740039
-
Convulsions due to high-dose busulphan [case report]
-
Marcus RE, Goldman JM. Convulsions due to high-dose busulphan [case report]. Lancet 1984;2:1463.
-
(1984)
Lancet
, vol.2
, pp. 1463
-
-
Marcus, R.E.1
Goldman, J.M.2
-
8
-
-
0022880793
-
High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study
-
Hartmann O, Benhamou E, Beaujean F, et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 1986;4:1804-10.
-
(1986)
J Clin Oncol
, vol.4
, pp. 1804-1810
-
-
Hartmann, O.1
Benhamou, E.2
Beaujean, F.3
-
9
-
-
0025121395
-
Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study
-
Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
-
(1990)
Cancer Res
, vol.50
, pp. 6203-6207
-
-
Vassal, G.1
Deroussent, A.2
Hartmann, O.3
-
10
-
-
0026518434
-
Generalized seizures secondary to high-dose busulfan therapy
-
Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother 1992;26:30-1.
-
(1992)
Ann Pharmacother
, vol.26
, pp. 30-31
-
-
Murphy, C.P.1
Harden, E.A.2
Thompson, J.M.3
-
11
-
-
0026526875
-
Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: Neurological and electroencephalographic prospective study
-
Meloni G, Raucci U, Pinto RM, Spalice A, Vignetti M, Iannetti P. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 1992;3: 145-8.
-
(1992)
Ann Oncol
, vol.3
, pp. 145-148
-
-
Meloni, G.1
Raucci, U.2
Pinto, R.M.3
Spalice, A.4
Vignetti, M.5
Iannetti, P.6
-
12
-
-
0029397084
-
Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukemia patients
-
Meloni G, Nasta L, Pinto RM, Spalice A, Raucci U, Iannetti P. Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukemia patients. Haematologica 1995;80:532-4.
-
(1995)
Haematologica
, vol.80
, pp. 532-534
-
-
Meloni, G.1
Nasta, L.2
Pinto, R.M.3
Spalice, A.4
Raucci, U.5
Iannetti, P.6
-
13
-
-
0031961910
-
Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation
-
Kobayashi R, Watanabe N, Iguchi A, et al. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant 1998;21:217-20.
-
(1998)
Bone Marrow Transplant
, vol.21
, pp. 217-220
-
-
Kobayashi, R.1
Watanabe, N.2
Iguchi, A.3
-
14
-
-
3142717604
-
Busulfan neurotoxicity and EEG abnormalities: A case report
-
La Morgia C, Mondini S, Guarino M, Bonifazi F, Cirignotta F. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci 2004;25:95-7.
-
(2004)
Neurol Sci
, vol.25
, pp. 95-97
-
-
La Morgia, C.1
Mondini, S.2
Guarino, M.3
Bonifazi, F.4
Cirignotta, F.5
-
15
-
-
0024555570
-
Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy
-
Hassan M, Ehrsson H, Smedmyr B, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 1989;4:113-14.
-
(1989)
Bone Marrow Transplant
, vol.4
, pp. 113-114
-
-
Hassan, M.1
Ehrsson, H.2
Smedmyr, B.3
-
17
-
-
0023507384
-
Clinical and pharmacologic effects of high-dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors
-
Peters WP, Henner WD, Grochow LB, et al. Clinical and pharmacologic effects of high-dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987;47:6402-6.
-
(1987)
Cancer Res
, vol.47
, pp. 6402-6406
-
-
Peters, W.P.1
Henner, W.D.2
Grochow, L.B.3
-
18
-
-
34250206633
-
Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality
-
McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007;13: 853-62.
-
(2007)
Biol Blood Marrow Transplant
, vol.13
, pp. 853-862
-
-
McCune, J.S.1
Batchelder, A.2
Deeg, H.J.3
-
19
-
-
0036672230
-
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
-
McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:167-73.
-
(2002)
Bone Marrow Transplant
, vol.30
, pp. 167-173
-
-
McCune, J.S.1
Gooley, T.2
Gibbs, J.P.3
-
20
-
-
0038644880
-
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
-
Radich JP, Gooley T, Bensinger W et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-5.
-
(2003)
Blood
, vol.102
, pp. 31-35
-
-
Radich, J.P.1
Gooley, T.2
Bensinger, W.3
-
21
-
-
0030902219
-
Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
-
Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60.
-
(1997)
Blood
, vol.89
, pp. 3055-3060
-
-
Slattery, J.T.1
Clift, R.A.2
Buckner, C.D.3
-
22
-
-
0029057117
-
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
-
Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
-
(1995)
Bone Marrow Transplant
, vol.16
, pp. 31-42
-
-
Slattery, J.T.1
Sanders, J.E.2
Buckner, C.D.3
-
23
-
-
0033823462
-
Plasma concentration monitoring of busulfan: Does it improve clinical outcome?
-
McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000;39:155-65.
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 155-165
-
-
McCune, J.S.1
Gibbs, J.P.2
Slattery, J.T.3
-
24
-
-
0029840656
-
Busulfan conjugation by glutathione S-transferases alpha, mu, and pi
-
Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996;24:1015-19.
-
(1996)
Drug Metab Dispos
, vol.24
, pp. 1015-1019
-
-
Czerwinski, M.1
Gibbs, J.P.2
Slattery, J.T.3
-
25
-
-
0036204648
-
Cellular and clinical pharmacology of fludarabine
-
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002;41:93-103.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 93-103
-
-
Gandhi, V.1
Plunkett, W.2
-
26
-
-
1342308417
-
2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat
-
2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J Pharmacol Exp Ther 2004;308:1204-12.
-
(2004)
J Pharmacol Exp Ther
, vol.308
, pp. 1204-1212
-
-
Qiu, R.1
Kalhorn, T.F.2
Slattery, J.T.3
-
27
-
-
0030799414
-
Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
-
Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-35.
-
(1997)
Cancer Res
, vol.57
, pp. 4229-4235
-
-
Ren, S.1
Yang, J.S.2
Kalhorn, T.F.3
Slattery, J.T.4
-
28
-
-
18844425783
-
Transporters and their impact on drug disposition
-
Beringer PM, Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother 2005;39:1097-108.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 1097-1108
-
-
Beringer, P.M.1
Slaughter, R.L.2
-
29
-
-
32544449791
-
Treatment of pediatric epilepsy: Expert opinion, 2005
-
Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(suppl 1):S1-56.
-
(2005)
J Child Neurol
, vol.20
, Issue.SUPPL. 1
-
-
Wheless, J.W.1
Clarke, D.F.2
Carpenter, D.3
-
30
-
-
23644441735
-
Treatment of epilepsy in adults: Expert opinion, 2005
-
Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005;7(suppl 1):S1-64.
-
(2005)
Epilepsy Behav
, vol.7
, Issue.SUPPL. 1
-
-
Karceski, S.1
Morrell, M.J.2
Carpenter, D.3
-
33
-
-
33845711837
-
Optimizing therapy of seizures in neurosurgery
-
Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006;67(12 suppl 4):S14-18.
-
(2006)
Neurology
, vol.67
, Issue.12 SUPPL. 4
-
-
Michelucci, R.1
-
34
-
-
23644438232
-
-
Brathen G, Ben-Menachem E, Brodtkorb E, et al. European Federation of Neurological Sciences (EFNS) guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. Eur J Neurol 2005;12:575-81. (Erratum in Eur J Neurol 2005;12:816.)
-
Brathen G, Ben-Menachem E, Brodtkorb E, et al. European Federation of Neurological Sciences (EFNS) guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. Eur J Neurol 2005;12:575-81. (Erratum in Eur J Neurol 2005;12:816.)
-
-
-
-
35
-
-
2542598418
-
Carbamazepine: Adverse effects
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Holmes GL. Carbamazepine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002: 285-97.
-
(2002)
Antiepileptic drugs
, pp. 285-297
-
-
Holmes, G.L.1
-
36
-
-
34948874814
-
Anticonvulsant hypersensitivity syndrome: Implications for pharmaceutical care
-
Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007;27:1425-39.
-
(2007)
Pharmacotherapy
, vol.27
, pp. 1425-1439
-
-
Bohan, K.H.1
Mansuri, T.F.2
Wilson, N.M.3
-
37
-
-
0031800865
-
A mechanistic approach to antiepileptic drug interactions
-
Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.
-
(1998)
Ann Pharmacother
, vol.32
, pp. 554-563
-
-
Anderson, G.D.1
-
38
-
-
85036876154
-
-
Scientific discussion, Available from, Accessed September 26
-
European Medicines Agency. Scientific discussion, 2005. Available from http://www.emea.europa.eu//humandocs/ PDFs/EPAR/busilvex/168603en6.pdf. Accessed September 26, 2008.
-
(2005)
-
-
-
39
-
-
0010961486
-
Valproic acid: Adverse effects
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Genton P, Gelisse P. Valproic acid: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002: 837-51.
-
(2002)
Antiepileptic drugs
, pp. 837-851
-
-
Genton, P.1
Gelisse, P.2
-
40
-
-
35748954046
-
Myelodysplastic syndrome associated with chronic valproic acid therapy: A case report and review of the literature
-
Allan RW. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature. Hematology 2007;12:493-6.
-
(2007)
Hematology
, vol.12
, pp. 493-496
-
-
Allan, R.W.1
-
41
-
-
4544242235
-
Phenobarbital and other barbiturates: Adverse effects
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Baulac M, Cramer JA, Mattson RH. Phenobarbital and other barbiturates: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:528-40.
-
(2002)
Antiepileptic drugs
, pp. 528-540
-
-
Baulac, M.1
Cramer, J.A.2
Mattson, R.H.3
-
42
-
-
0023621233
-
Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5′-diphenylhydantoin on enzyme activity in male rodents
-
Davies MH, Schnell RC. Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5′-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C 1987;88:91-3.
-
(1987)
Comp Biochem Physiol C
, vol.88
, pp. 91-93
-
-
Davies, M.H.1
Schnell, R.C.2
-
44
-
-
0030859661
-
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma
-
Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone marrow transplant 1997;20:843-6.
-
(1997)
Bone marrow transplant
, vol.20
, pp. 843-846
-
-
Atra, A.1
Whelan, J.S.2
Calvagna, V.3
-
45
-
-
0037435505
-
Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury: report of the quality standards subcommittee of the American Academy of Neurology
-
Chang BS, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2003;60:10-16.
-
(2003)
Neurology
, vol.60
, pp. 10-16
-
-
Chang, B.S.1
Lowenstein, D.H.2
-
46
-
-
0024453350
-
Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia
-
Beelen DW, Quabeck K, Graeven U, Sayer HG, Mahmoud HK, Schaefer UW. Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood 1989;74:1507-16.
-
(1989)
Blood
, vol.74
, pp. 1507-1516
-
-
Beelen, D.W.1
Quabeck, K.2
Graeven, U.3
Sayer, H.G.4
Mahmoud, H.K.5
Schaefer, U.W.6
-
48
-
-
3042848771
-
Phenytoin and other hydantoins: Clinical efficacy and use in epilepsy
-
Levy R, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott, Williams & Wilkins
-
Wilder BJ, Bruni J. Phenytoin and other hydantoins: clinical efficacy and use in epilepsy. In: Levy R, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott, Williams & Wilkins, 2002:591-6.
-
(2002)
Antiepileptic drugs
, pp. 591-596
-
-
Wilder, B.J.1
Bruni, J.2
-
49
-
-
8344289578
-
Phenytoin and other hydantoins: Adverse effects
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott, Williams & Wilkins
-
Bruni J. Phenytoin and other hydantoins: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott, Williams & Wilkins, 2002:605-10.
-
(2002)
Antiepileptic drugs
, pp. 605-610
-
-
Bruni, J.1
-
50
-
-
34248531953
-
Comparison and predictors of rash associated with 15 antiepileptic drugs
-
Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9.
-
(2007)
Neurology
, vol.68
, pp. 1701-1709
-
-
Arif, H.1
Buchsbaum, R.2
Weintraub, D.3
-
51
-
-
0029863162
-
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
-
Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-94.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1484-1494
-
-
Slattery, J.T.1
Kalhorn, T.F.2
McDonald, G.B.3
-
52
-
-
17644418381
-
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin
-
de Jonge ME, Huitema AD, van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 2005;55:507-10.
-
(2005)
Cancer Chemother Pharmacol
, vol.55
, pp. 507-510
-
-
de Jonge, M.E.1
Huitema, A.D.2
van Dam, S.M.3
Beijnen, J.H.4
Rodenhuis, S.5
-
53
-
-
0025644705
-
The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity
-
Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990;27:226-8.
-
(1990)
Cancer Chemother Pharmacol
, vol.27
, pp. 226-228
-
-
Fitzsimmons, W.E.1
Ghalie, R.2
Kaizer, H.3
-
54
-
-
0035150407
-
Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices
-
Gallagher EP, Sheehy KM. Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci 2001;59(1): 118-26.
-
(2001)
Toxicol Sci
, vol.59
, Issue.1
, pp. 118-126
-
-
Gallagher, E.P.1
Sheehy, K.M.2
-
55
-
-
0027508014
-
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics
-
Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993;33: 181-6.
-
(1993)
Cancer Chemother Pharmacol
, vol.33
, pp. 181-186
-
-
Hassan, M.1
Oberg, G.2
Bjorkholm, M.3
Wallin, I.4
Lindgren, M.5
-
56
-
-
0034749408
-
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
-
Sandstrom M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001;28:657-64.
-
(2001)
Bone Marrow Transplant
, vol.28
, pp. 657-664
-
-
Sandstrom, M.1
Karlsson, M.O.2
Ljungman, P.3
-
57
-
-
33745159360
-
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen
-
Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006;12:770-7.
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 770-777
-
-
Aggarwal, C.1
Gupta, S.2
Vaughan, W.P.3
-
58
-
-
33845984552
-
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule
-
Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007;13:56-64.
-
(2007)
Biol Blood Marrow Transplant
, vol.13
, pp. 56-64
-
-
Madden, T.1
de Lima, M.2
Thapar, N.3
-
59
-
-
28844489966
-
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: A population pharmacokinetic study
-
Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57:191-8.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 191-198
-
-
Nguyen, L.1
Leger, F.2
Lennon, S.3
Puozzo, C.4
-
60
-
-
0035164618
-
Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression
-
Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001;11: 663-9.
-
(2001)
Pharmacogenetics
, vol.11
, pp. 663-669
-
-
Coles, B.F.1
Morel, F.2
Rauch, C.3
-
61
-
-
4444259109
-
Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation
-
Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004;104:1574-7.
-
(2004)
Blood
, vol.104
, pp. 1574-1577
-
-
Srivastava, A.1
Poonkuzhali, B.2
Shaji, R.V.3
-
62
-
-
33845243707
-
Antiepileptic treatment in paediatric oncology: An interdisciplinary challenge
-
Tibussek D, Distelmaier F, Schonberger S, Gobel U, Mayatepek E. Antiepileptic treatment in paediatric oncology: an interdisciplinary challenge. Klin Padiatr 2006;218:340-9.
-
(2006)
Klin Padiatr
, vol.218
, pp. 340-349
-
-
Tibussek, D.1
Distelmaier, F.2
Schonberger, S.3
Gobel, U.4
Mayatepek, E.5
-
63
-
-
33947721909
-
Seizures and epilepsy in oncological practice: Causes, course, mechanisms and treatment
-
Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007;78:342-9.
-
(2007)
J Neurol Neurosurg Psychiatry
, vol.78
, pp. 342-349
-
-
Singh, G.1
Rees, J.H.2
Sander, J.W.3
-
64
-
-
0028823467
-
Clobazam for seizure prophylaxis during busulfan chemotherapy [case report]
-
Schwarer AP, Opat SS, Watson AL, Cole-Sinclair MF. Clobazam for seizure prophylaxis during busulfan chemotherapy [case report]. Lancet 1995;346:1238.
-
(1995)
Lancet
, vol.346
, pp. 1238
-
-
Schwarer, A.P.1
Opat, S.S.2
Watson, A.L.3
Cole-Sinclair, M.F.4
-
65
-
-
11844259396
-
Intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics in association with early clinical outcome and toxicity
-
Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005;35:17-23.
-
(2005)
Bone Marrow Transplant
, vol.35
, pp. 17-23
-
-
Zwaveling, J.1
Bredius, R.G.2
Cremers, S.C.3
-
66
-
-
0028017526
-
Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia
-
Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994;84:2357-62.
-
(1994)
Blood
, vol.84
, pp. 2357-2362
-
-
Shaw, P.J.1
Scharping, C.E.2
Brian, R.J.3
Earl, J.W.4
-
67
-
-
0036321897
-
Lorazepam for seizure prophylaxis during high-dose busulfan administration
-
Chan KW, Mullen CA, Worth LL, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002;29:963-5.
-
(2002)
Bone Marrow Transplant
, vol.29
, pp. 963-965
-
-
Chan, K.W.1
Mullen, C.A.2
Worth, L.L.3
-
68
-
-
68149160256
-
Clonazepam and levetiracetam for prevention of busulfan-induced seizures: A single-center experience [abstract]
-
abstract 467
-
Bubalo JS, Kovascovics TJ, Meyers G, et al. Clonazepam and levetiracetam for prevention of busulfan-induced seizures: a single-center experience [abstract]. Biol Blood Marrow Transplant 2008;14(2 suppl 2):abstract 467.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, Issue.2 SUPPL. 2
-
-
Bubalo, J.S.1
Kovascovics, T.J.2
Meyers, G.3
-
69
-
-
42049100573
-
Benzodiazepines: Chemistry, biotransformation, and pharmacokinetics
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Anderson G, Miller J. Benzodiazepines: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:187-205.
-
(2002)
Antiepileptic drugs
, pp. 187-205
-
-
Anderson, G.1
Miller, J.2
-
70
-
-
33745499146
-
Benzodiazepines: Adverse effects
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Michelucci R, Tassinari, CA. Benzodiazepines: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:215-23.
-
(2002)
Antiepileptic drugs
, pp. 215-223
-
-
Michelucci, R.1
Tassinari, C.A.2
-
71
-
-
33947729635
-
The role of pharmacogenetics in the metabolism of antiepileptic drugs: Pharmacokinetic and therapeutic implications
-
Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007;46:271-9.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 271-279
-
-
Klotz, U.1
-
73
-
-
0942276885
-
Postoperative seizures: Epidemiology, pathology, and prophylaxis
-
Manaka S, Ishijima B, Mayanagi Y. Postoperative seizures: epidemiology, pathology, and prophylaxis. Neurol Med Chir (Tokyo) 2003;43:589-600.
-
(2003)
Neurol Med Chir (Tokyo)
, vol.43
, pp. 589-600
-
-
Manaka, S.1
Ishijima, B.2
Mayanagi, Y.3
-
74
-
-
0038144913
-
Zonisamide: Adverse effects
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Lee BI. Zonisamide: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:892-8.
-
(2002)
Antiepileptic drugs
, pp. 892-898
-
-
Lee, B.I.1
-
75
-
-
0038196954
-
Zonisamide: Drug interactions
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds, 5th ed. Philadelphia: Lippincott Williams & Wilkins
-
Mather G, Shah J. Zonisamide: drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:880-4.
-
(2002)
Antiepileptic drugs
, pp. 880-884
-
-
Mather, G.1
Shah, J.2
-
76
-
-
33644909875
-
Clinically relevant drug interactions with antiepileptic drugs
-
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55.
-
(2006)
Br J Clin Pharmacol
, vol.61
, pp. 246-255
-
-
Perucca, E.1
-
77
-
-
33846850154
-
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
-
Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-8.
-
(2007)
Neurology
, vol.68
, pp. 402-408
-
-
Brodie, M.J.1
Perucca, E.2
Ryvlin, P.3
Ben-Menachem, E.4
Meencke, H.J.5
-
78
-
-
85036882802
-
-
UCB Inc. Keppra (levetiracetam) package insert. Smyrna, GA; 2008
-
UCB Inc. Keppra (levetiracetam) package insert. Smyrna, GA; 2008.
-
-
-
-
79
-
-
36048971625
-
Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy
-
Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 2007;48:2111-15.
-
(2007)
Epilepsia
, vol.48
, pp. 2111-2115
-
-
Otoul, C.1
De Smedt, H.2
Stockis, A.3
|